A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Trial Profile

A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; SD 101 Dynavax (Primary)
  • Indications Head and neck cancer; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-184
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 22 Aug 2017 Planned number of patients changed from 156 to 174.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Interim results from Phase 1b portion (n=22) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top